Chang-Gyu Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chang-Gyu Jung has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Hae-Sim Park
Department of Allergy and Clinical Immunology Ajou University School of Medicine Suwon Korea
6 shared publications - Young-Min Ye
Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon 16499, Republic of Korea
4 shared publications - Eun-Mi Yang
Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
3 shared publications - Ga-Young Ban
Department of Pulmonary, Allergy, and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
3 shared publications - Ji-Ho Lee
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
3 shared publications - Alicja Kasperska-Zajac
European Center for Diagnosis and Treatment of Urticaria Medical University of Silesia Katowice Poland
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10277
Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.
- 16 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10277
Open AccessExacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.
- 30 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Clinical and Immunologic Characteristics of Cat‐Pork Syndrome in Adults
Summary: Fel d 2 is an important diagnostic component for adult cat–pork syndrome. Bos d 6 may serve as a potential supportive marker for component‐based diagnosis of cat‐pork syndrome when Sus s 1 is unavailable.
- 30 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Clinical and Immunologic Characteristics of Cat‐Pork Syndrome in Adults
Summary: Fel d 2 is an important diagnostic component for adult cat–pork syndrome. Bos d 6 may serve as a potential supportive marker for component‐based diagnosis of cat‐pork syndrome when Sus s 1 is unavailable.
- Open Access
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Open AccessFactors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- Open Access
The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
Open AccessThe Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
- 3 April 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (6) , 648-658
Role of club cell 16‐kDa secretory protein in asthmatic airways
Background: Club cell 16‐kDa secretory protein (CC16) is a pneumoprotein and functions as an anti‐inflammatory or antioxidant protein. However, altered levels of serum CC16 as well as their effect on airways inflammation have not been fully evaluated.Methods: We recruited 63 adult asthmatics on maintenance medications and 61 healthy controls (HCs). The asthmatic subjects were divided into two groups according to the result of bronchodilator responsiveness (BDR) test: the present BDR (n = 17) and absent BDR (n = 46) groups. Serum CC16 levels were measured by ELISA. As an in vitro study, the effect of Dermatophagoides pteronyssinus antigen 1 (Der p1) on the production of CC16 in airways epithelial cells (AECs) according to a time‐dependent manner was assessed; the effects of CC16 protein on oxidative stress system, airways inflammation and remodelling were tested.Results: Serum CC16 levels showed significantly higher in the asthmatics than in the HCs (p < .001) with a positive correlation with FEV1% (r = .352, p = .005). The present BDR group had significantly lower levels of serum CC16, FEV1% and MMEF%, but showed higher level of FeNO than the absent BDR group. Serum CC16 levels (below 496.0 ng/mL) could discriminate the present BDR group from the absent BDR group (area under the curve = 0.74, p = .004). In vitro testing demonstrated that Der p1 exposure significantly induced CC16 release from AECs for 1 h, which was progressively decreased after 6 h and followed by MMP‐9 and TIMP‐1 production. These findings were associated with oxidant/antioxidant disequilibrium and restored by CC16 treatment (but not dexamethasone).Conclusion: Decreased CC16 production contributes to persistent airways inflammation and lung function decline. CC16 may be a potential biomarker for asthmatics with BDR.
- 3 April 2023
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (6) , 648-658
Role of club cell 16‐kDa secretory protein in asthmatic airways
Background: Club cell 16‐kDa secretory protein (CC16) is a pneumoprotein and functions as an anti‐inflammatory or antioxidant protein. However, altered levels of serum CC16 as well as their effect on airways inflammation have not been fully evaluated.Methods: We recruited 63 adult asthmatics on maintenance medications and 61 healthy controls (HCs). The asthmatic subjects were divided into two groups according to the result of bronchodilator responsiveness (BDR) test: the present BDR (n = 17) and absent BDR (n = 46) groups. Serum CC16 levels were measured by ELISA. As an in vitro study, the effect of Dermatophagoides pteronyssinus antigen 1 (Der p1) on the production of CC16 in airways epithelial cells (AECs) according to a time‐dependent manner was assessed; the effects of CC16 protein on oxidative stress system, airways inflammation and remodelling were tested.Results: Serum CC16 levels showed significantly higher in the asthmatics than in the HCs (p < .001) with a positive correlation with FEV1% (r = .352, p = .005). The present BDR group had significantly lower levels of serum CC16, FEV1% and MMEF%, but showed higher level of FeNO than the absent BDR group. Serum CC16 levels (below 496.0 ng/mL) could discriminate the present BDR group from the absent BDR group (area under the curve = 0.74, p = .004). In vitro testing demonstrated that Der p1 exposure significantly induced CC16 release from AECs for 1 h, which was progressively decreased after 6 h and followed by MMP‐9 and TIMP‐1 production. These findings were associated with oxidant/antioxidant disequilibrium and restored by CC16 treatment (but not dexamethasone).Conclusion: Decreased CC16 production contributes to persistent airways inflammation and lung function decline. CC16 may be a potential biomarker for asthmatics with BDR.
- 1 November 2022
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 23 (11) , 714-720
Emerging Hop Japanese Pollinosis in Asia
Hop Japanese (Hop J) pollen has been considered one of the major causative pollen allergens in Far East Asia in the autumn season. The sensitization rate, pollen count, and allergenicity of Hop J pollens are increasing in this region because of increased air pollution and global warming. However, commercial skin test agents for the diagnosis and allergen extracts for the allergen immunotherapy are not available. This review summarizes recent data on clinical impact of Hop J pollinosis in order to facilitate the development of diagnostic and therapeutic agents for this region.
- 1 November 2022
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 23 (11) , 714-720
Emerging Hop Japanese Pollinosis in Asia
Hop Japanese (Hop J) pollen has been considered one of the major causative pollen allergens in Far East Asia in the autumn season. The sensitization rate, pollen count, and allergenicity of Hop J pollens are increasing in this region because of increased air pollution and global warming. However, commercial skin test agents for the diagnosis and allergen extracts for the allergen immunotherapy are not available. This review summarizes recent data on clinical impact of Hop J pollinosis in order to facilitate the development of diagnostic and therapeutic agents for this region.
- Open Access
- 1 January 2019
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 11 (3) , 394-405
Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics
Lee Y, et al. Allergy Asthma Immunol Res. 2019 May;11(3):394-405. https://doi.org/10.4168/aair.2019.11.3.394
- 1 January 2019
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 11 (3) , 394-405
Open AccessSerum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics
Lee Y, et al. Allergy Asthma Immunol Res. 2019 May;11(3):394-405. https://doi.org/10.4168/aair.2019.11.3.394
- 1 September 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (5) , 1787-1789.e1
Coca-Cola allergy identified as fructose-induced anaphylaxis
- 1 September 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (5) , 1787-1789.e1
Coca-Cola allergy identified as fructose-induced anaphylaxis
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (7) , 1124-1130
Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors
Lee JH, et al. J Korean Med Sci. 2017 Jul;32(7):1124-1130. https://doi.org/10.3346/jkms.2017.32.7.1124
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (7) , 1124-1130
Open AccessSubcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors
Lee JH, et al. J Korean Med Sci. 2017 Jul;32(7):1124-1130. https://doi.org/10.3346/jkms.2017.32.7.1124